Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network

References

• Stein H, Poppema S, Delsol G, et al. Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 321–334.
   Google Scholar
• Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology 2011;58:15–25.
   PubMed Web of Science ®Google Scholar
• Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008;205:2251–2268.
   PubMed Web of Science ®Google Scholar
• Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003;102:3753–3758.
   PubMed Web of Science ®Google Scholar
• Chen RC, Chin MS, Ng A, et al. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 2010;28:136–141.
   PubMed Web of Science ®Google Scholar
• Al Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol 2010;28:793–799.
   PubMed Web of Science ®Google Scholar
• Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010;116:631–639.
   PubMed Web of Science ®Google Scholar
• Nogova L, Rudiger T, Engert A. Biology, clinical course and management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006:266–272.
   PubMedGoogle Scholar
• Orlandi E, Lazzarino M, Brusamolino E, et al. Nodular lymphocyte predominance Hodgkin’s disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 1997;26:359–368.
   PubMed Web of Science ®Google Scholar
• Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol 1999;17:776–783.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hodgkin lymphoma, v 2. 2010. Available from: http://www.nccn.org/professionals/physi cian_gls/f_guidelines.asp.
   Google Scholar
• Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003;21:3431–3439.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Skinnider B, Al Mansour M, et al. Incorporation of ABVD increased cure rates of patients with limited stage nodular lymphocyte predominant Hodgkin lymphoma. Blood 2010; 116(Suppl. 1): Abstract 3887.
   PubMed Web of Science ®Google Scholar
• General Register Office for Scotland. Scotland’s census results on-line. 2011. Available from: http://www.scrol.gov.uk/scrol/common/home.jsp.
   Google Scholar
• Engert A, Eichenauer DA, Dreyling M. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl. 5): v168–v171.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998;339: 1506–1514.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Radford JA, Rohatiner AZ, Ryder WD, et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol 2002;20:2988–2994.
   PubMed Web of Science ®Google Scholar
• Al Mansour M, Connors JM, Gascoyne RD, Skinnider B, Savage KJ. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol 2010;28:793–799.
   PubMed Web of Science ®Google Scholar
• Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma--experience from the European network group on pediatric Hodgkin lymphoma. Cancer 2007;110:179–185.
   PubMed Web of Science ®Google Scholar
• Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 2005;104:1221–1229.
   PubMed Web of Science ®Google Scholar
• Koerholz D. Surgery alone, surgery with cyclophosphamide, vinblastine, and prednisolone (CVP), or CVP alone in treating young patients with stage IA or stage IIA nodular lymphocyte-predominant Hodgkin lymphoma. 2011. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01088750?term= nodular+lymphocyte+hodgkin&rank=1.
   Google Scholar
• Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin’s lymphoma? J Clin Oncol 2010;28:e8.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) patients treated with R-CHOP. Blood 2010; 116(Suppl. 5): Abstract 2812.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009;113:5920–5926.
   PubMed Web of Science ®Google Scholar